Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse

MLA

Hagop M. Kantarjian, et al. “Long Term Outcome of Hyper-CVAD-R for Burkitt Leukemia/Lymphoma and High-Grade B-Cell Lymphoma: Focus on CNS Relapse.” Blood Advances, Aug. 2021. EBSCOhost, https://doi.org/10.1182/bloodadvances.2021004427.

APA

Hagop M. Kantarjian, Nicholas J. Short, Guillaume Richard-Carpentier, Joseph D. Khoury, Elias Jabbour, Nitin Jain, Siba El Hussein, Farhad Ravandi, Philip A. Thompson, Kiyomi Morita, & Bachar Samra. (2021). Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Advances. https://doi.org/10.1182/bloodadvances.2021004427

Chicago

Hagop M. Kantarjian, Nicholas J. Short, Guillaume Richard-Carpentier, Joseph D. Khoury, Elias Jabbour, Nitin Jain, Siba El Hussein, et al. 2021. “Long Term Outcome of Hyper-CVAD-R for Burkitt Leukemia/Lymphoma and High-Grade B-Cell Lymphoma: Focus on CNS Relapse.” Blood Advances, August. doi:10.1182/bloodadvances.2021004427.